Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K current report with the SEC on July 8, 2026 reporting Item 8.01 (Other Events). IMS received an FDA warning letter on July 2, 2026, after a December 2025 inspection of its South El Monte, California facility.
Amphastar Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- IMS received an FDA warning letter on July 2, 2026, after a December 2025 inspection of its South El Monte, California facility
- CGMP deficiencies involve investigations, environmental monitoring, handling procedures, and manufacturing equipment
- No current production halt, product restriction, or additional recall ordered, preserving near-term supply continuity
- IMS must submit an initial response within 15 working days, complete a risk assessment, and provide a remediation plan
- Unresolved deficiencies could trigger additional regulatory or legal action and create operational risk for Amphastar
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amphastar Pharmaceuticals, Inc. 8-K filings
Get the next AMPH 8-K as it lands
Follow AMPH for push alerts, or ask the research agent what this filing means.